Abstract
We conducted a genome-wide association study of 3090 sporadic prostate cancer patients and controls using the Affymetrix 10 000 SNP GeneChip. Initial screening of 40 prostate cancer cases and 40 non-cancer controls revealed 237 SNPs to be associated with prostate cancer (P<0.05). Among these SNPs, 33 were selected for further association analysis of 2069 men who had undergone a cancer-screening prostate biopsy. Results identified five loci as being significantly associated with increased prostate cancer risk in this larger sample (rs1930293, OR=1.7, P=0.03; rs717809-2p12, OR=1.3, P=0.03; rs494770-4q34, OR=1.3, P=0.01; rs2348763-7p21, OR=1.5, P=0.01; rs1552895-9p22, OR=1.5, P=0.002). To validate these association data, 61 additional HapMap tagSNPs spanning the latter five loci were genotyped in this subject cohort and an additional 1021 men (total subject number=3090). This analysis revealed tagSNP rs4568789 (chromosome 1q25) and tagSNP rs13225697 (chromosome 7p21) to be significantly associated with prostate cancer (P-values 0.009 and 0.008, respectively). Haplotype analysis revealed significant associations of prostate cancer with two allele risk haplotypes on both chromosome 1q25 (adjusted OR of 2.7 for prostate cancer, P=0.0003) and chromosome 7p21 (adjusted OR of 1.3, P=0.0004). As linkage data have identified a putative prostate cancer gene on chromosome 1q25 (HPC1), and microarray data have revealed the ETV1 oncogene to be overexpressed in prostate cancer tissue, it appears that chromosome 1q25 and 7p21 may be sites of gene variants conferring risk for sporadic and inherited forms of prostate cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 4 print issues and online access
$259.00 per year
only $64.75 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Schaid DJ . The complex genetic epidemiology of prostate cancer. Hum Mol Genet 2004; 13 (Spec No 1): R103–R121.
Carpten J, Nupponen N, Isaacs S, Sood R, Robbins C, Xu J et al. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet 2002; 30: 181–184.
Noonan-Wheeler FC, Wu W, Roehl KA, Klim A, Haugen J, Suarez BK et al. Association of hereditary prostate cancer gene polymorphic variants with sporadic aggressive prostate carcinoma. Prostate 2006; 66: 49–56.
Vesprini D, Nam RK, Trachtenberg J, Jewett MAS, Tavtigian SV, Emami M et al. HPC2 variants and screen-detected prostate cancer. Am J Hum Genet 2001; 68: 912–917.
Zhao X, Li C, Paez JG, Chin K, Janne PA, Chen TH et al. An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Res 2004; 64: 3060–3071.
Wong KK, Tsang YT, Shen J, Cheng RS, Chang YM, Man TK et al. Allelic imbalance analysis by high-density single-nucleotide polymorphic allele (SNP) array with whole genome amplified DNA. Nucleic Acids Res 2004; 32: e69.
Hu N, Wang C, Hu Y, Yang HH, Giffen C, Tang ZZ et al. Genome-wide association study in esophageal cancer using GeneChip mapping 10 K array. Cancer Res 2005; 65: 2542–2546.
Roehl KA, Loeb S, Antenor JA, Corbin N, Catalona WJ . Characteristics of patients with familial versus sporadic prostate cancer. J Urol 2006; 176 (Part 1): 2438–2442; discussion 42.
Nam RK, Zhang WW, Jewett MA, Trachtenberg J, Klotz LH, Emami M et al. The use of genetic markers to determine risk for prostate cancer at prostate biopsy. Clin Cancer Res 2005; 11: 8391–8397.
Nam RK, Zhang W, Jewett MAS, Emami M, Vesprini D, Chu W et al. Comprehensive assessment of candidate genes and serological markers for the detection of prostate cancer. Cancer Epidemiol Biomarkers Prev 2003; 12: 1429–1437.
Nam RK, Zhang WW, Klotz LH, Trachtenberg J, Jewett MAS, Sweet J et al. Variants of the hK2 protein gene (KLK2) are associated with serum hK2 levels and predict the presence of prostate cancer at biopsy. Clin Cancer Res 2006; 12: 6452–6458.
Province MA, Shannon WD, Rao DC . Classification methods for confronting heterogeneity. Adv Genet 2001; 74: 1302–1307.
Smith JR, Freije D, Carpten JD, Gronberg H, Xu J, Isaacs SD et al. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 1996; 274: 1371–1374.
Cooney KA, McCarthy JD, Lange E, Huang L, Miesfeldt S, Montie JE et al. Prostate cancer susceptibility locus on chromosome 1q: a confirmatory study. J Natl Cancer Inst 1997; 89: 955–959.
Li H, Tai BC . RNASEL gene polymorphisms and the risk of prostate cancer: a meta-analysis. Clin Cancer Res 2006; 12: 5713–5719.
Carpten JD, Makalowska I, Robbins CM, Scott N, Sood R, Connors TD et al. A 6-Mb high-resolution physical and transcription map encompassing the hereditary prostate cancer 1 (HPC1) region. Genomics 2000; 64: 1–14.
Cai C, Hsieh CL, Omwancha J, Zheng Z, Chen SY, Baert JL et al. ETV1 is a novel androgen receptor-regulated gene that mediates prostate cancer cell invasion. Mol endocrinol 2007; 21: 1835–1846.
Tomlins SA, Mehra R, Rhodes DR, Smith LR, Roulston D, Helgeson BE et al. TMPRSS2: ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res 2006; 66: 3396–3400.
Yeager M, Orr N, Hayes RB, Jacobs KB, Kraft P, Wacholder S et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 2007; 39: 645–649.
Gudmundsson J, Sulem P, Manolescu A, Amundadottir LT, Gudbjartsson D, Helgason A et al. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet 2007; 39: 631–637.
Haiman CA, Patterson N, Freedman ML, Myers SR, Pike MC, Waliszewska A et al. Multiple regions within 8q24 independently affect risk for prostate cancer. Nat Genet 2007; 39: 638–644.
Acknowledgements
This study was funded, in part, by the National Cancer Institute of Canada and the Terry Fox Foundation, Grants no. 010284 and no. 015164. Dr Nam is a Canadian Institute of Health Research (CIHR) New Investigator and Dr Siminovitch is a McLaughlin Centre for Molecular Medicine Scientist and holds a Canada Research Chair.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Nam, R., Zhang, W., Loblaw, D. et al. A genome-wide association screen identifies regions on chromosomes 1q25 and 7p21 as risk loci for sporadic prostate cancer. Prostate Cancer Prostatic Dis 11, 241–246 (2008). https://doi.org/10.1038/sj.pcan.4501010
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.pcan.4501010
Keywords
This article is cited by
-
Gas5 Exerts Tumor-suppressive Functions in Human Glioma Cells by Targeting miR-222
Molecular Therapy (2015)